skip to main content

Nail Psoriasis Biologic Access — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateNail DisordersNail Psoriasis Biologic AccessSCE Dermatology

A 50-year-old man has psoriasis with predominant nail disease. He has significant nail dystrophy causing pain and functional impairment. His PASI is only 3 but his modified NAPSI is 45. Can he access biologic therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Yes — nails are a recognised high-impact site; significant nail disease with high functional/QOL impact can justify biologic access even with low PASI under BAD guidelines

BAD guidelines recognise nail psoriasis as a high-impact manifestation that can justify biologic therapy even when PASI is <10. Significant nail disease causes: pain (subungual hyperkeratosis/onycholysis causing pressure), functional impairment (difficulty with fine motor tasks, footwear problems), cosmetic distress, and psychosocial impact. The decision to escalate to biologic therapy is based on the combination of nail severity (NAPSI), functional impairment, QOL impact (DLQI), and failure of other treatments. IL-17 inhibitors (Ixekizumab) have shown the highest nail clearance rates. The slow response timeline of nail psoriasis (6-12 months) should be communicated.

Reference: BAD 2020 Biologic Guidelines; NICE